What question did this study set out to answer?

This review aims to summarize recent advancements and literature concerning immune checkpoint inhibitors in cancer treatment.

Immune Checkpoint Inhibitors in Cancer Therapy

View Full Paper

Ask AI

Bookmark

Authors

Review discusses immune checkpoint inhibitors' effectiveness and biomarker role in cancer therapy, suggesting crucial implications.

This review aims to summarize recent advancements and literature concerning immune checkpoint inhibitors in cancer treatment.
Literature review focusing on immune checkpoint proteins and monoclonal antibodies.
Assessment of approved immune checkpoint inhibitors and their clinical applications.
Evaluation of biomarkers predicting responses to immunotherapy.
Highlighted the approval of PD-1 and PDL-1 inhibitors by the US FDA.
Emphasized the importance of assessing biomarkers like Tumour mutation burden and PDL-1 expression.
Noted varying patient responses to immune checkpoint inhibitors, underscoring the need for personalized approaches.

Shiravand et al. (2022) studied this question.

View Full Paper

Ask AI

Bookmark